Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.97 USD

28.97
32,299,589

+0.04 (0.14%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $28.93 -0.04 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

    Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

    Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

      Lilly's Breast Cancer Drug Gets Priority Review Status by FDA

      Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.

        Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

        Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

          Arpita Dutt headshot

          Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook

          3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.

            Pfizer's (PFE) Leukemia Candidate Receives Approval in EU

            Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.

              Why is Corcept's Stock Up More Than 60% So Far This Year?

              Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.

                Arena Ends Study on Extended Release Formulation of PAH Drug

                Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

                  Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

                  We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

                    Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                    Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                      Arpita Dutt headshot

                      M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

                      The biotech sector's fundamentals remain strong.

                        Merck's CETP Inhibitor Reduces CV Risk in Phase III Study

                        Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.

                          AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use

                          AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.

                            Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                            Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                              Epizyme Progressing Well on Two Lead Pipeline Candidates

                              We issued an updated research report on Epizyme, Inc. (EPZM) on Jun 23, 2017.

                                Eric Dutram headshot

                                Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger

                                This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!

                                  Stock Market News for June 22, 2017

                                  Energy shares continued to decline on Wednesday, sending the Dow and the S&P 500 lower

                                    Merck's Keytruda on a Roll: Can it Retain the Momentum?

                                    As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.

                                      Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US

                                      Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older

                                        Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More

                                        The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.

                                          Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                                          Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                                            J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                                            Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

                                              The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

                                              The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

                                                Arpita Dutt headshot

                                                3 Biotech Stocks That More than Doubled Year to Date

                                                Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

                                                  Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.